ArticleNature materials2026
Force-responsive biomaterials drive tissue repair by harnessing endogenous growth factors.
Article in Nature materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Materials enabling the cell-responsive delivery of endogenous biologics, such as growth factors, have the potential to modulate wound repair cost-effectively and safely. Unlike passive drug delivery strategies that require supraphysiological doses of recombinant protein or stimuli-responsive systems that rely on external triggers, we demonstrate a strategy that harnesses cellular traction forces as an intrinsic delivery trigger. Traction-force-activated payloads are bioinspired aptamer constructs attached to biomaterial scaffolds that selectively harvest, concentrate and reactivate multiple endogenous growth factors from cells, injury sites and blood lysate in vivo (rat femur and mouse skin) and ex vivo (human skin), at doses orders of magnitude lower than current clinical standards. Unmodified oligonucleotide aptamers retain functionality in enzyme-rich wound environments, substantially expanding the translational potential of nucleic-acid-based therapeutics. The ability to harvest and redeliver endogenous growth factors without exogenous triggers, recombinant proteins or cold-chain logistics via mechanoresponsive biomaterials opens possibilities for accessible, cost-effective combinatorial biologic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.